

**TIANJIN ZHONG XIN PHARMACEUTICAL GROUP CORPORATION LIMITED**

(Company Registration No. 91120000103100784F)

(Incorporated in People's Republic of China)

---

**LIST OF PARTICIPANTS PROPOSED TO PARTICIPATE IN THE GRANT OF RESERVED  
RESTRICTED A-SHARES UNDER THE SCHEME**

---

*The board of directors (the “Board”) and every individual director of Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (the “Company”) hereby confirm that they will individually and collectively accept full responsibility for the accuracy of the information given in this announcement, and confirm, having made all reasonable enquiries, that to the best of their knowledge and belief, the facts stated in this announcement are fair and accurate in all material respects as at the date of this announcement, and that there are no material facts the omission of which would make any statement in this announcement misleading.*

The Board refers to:

- (1) the announcement dated 16 October 2019 made by the Company in relation to the resolutions passed at the 7<sup>th</sup> Board meeting for the financial year ended 31 December 2019 (“**FY2019**”);
- (2) the announcement dated 16 October 2019 made by the Company in relation to the resolutions passed at the 6<sup>th</sup> supervisory committee (the “**Supervisory Committee**”) meeting for FY2019;
- (3) the circular dated 15 November 2019 (the “**Circular**”) to the shareholders of the Company (the “**Shareholders**”) in relation to, amongst others, the proposed adoption of the 2019 Restricted A-Share Incentive Scheme (the “**Scheme**”);
- (4) the announcement dated 25 November 2019 made by the Company in relation to the explanatory statement of the Supervisory Committee on the verification of the list of participants (the “**List of Participants**”) who have been proposed to participate in the Scheme and on the verification of the internal publication in respect of the List of Participants by the Company;
- (5) the corrigendum announcement dated 27 November 2019 made by the Company;
- (6) the announcement dated 2 December 2019 made by the Company in relation to the poll results of the extraordinary general meeting held on 2 December 2019;
- (7) the announcement dated 2 December 2019 made by the Company in relation to the self-examination report on the trading in the shares of the Company by the insiders in relation to the Scheme;
- (8) the announcement dated 9 December 2019 made by the Company in relation to the resolutions passed at the 10<sup>th</sup> Board meeting for FY2019;
- (9) the announcement dated 9 December 2019 made by the Company in relation to the resolutions passed at the 9<sup>th</sup> Supervisory Committee meeting for FY2019;
- (10) the announcement dated 9 December 2019 made by the Company in relation to the proposed adjustments to the List of Participants proposed to participate in the Initial Grant

(the “**Adjusted Participants**”) and the number of Initial Granted Restricted A-Shares (the “**Adjusted Initial Granted Restricted A-Shares**”) under the Scheme;

- (11) the announcement dated 9 December 2019 made by the Company in relation to the proposed grant of the Adjusted Initial Granted Restricted A-Shares to the Adjusted Participants under the Scheme;
- (12) the announcement dated 9 December 2019 made by the Company in relation to the list of the Adjusted Participants proposed to participate in the Initial Grant under the Scheme;
- (13) the announcement dated 8 January 2020 made by the Company in relation to the results of the Initial Grant under the Scheme;
- (14) the announcement dated 17 February 2020 made by the Company in relation to the resolutions passed at the 2<sup>nd</sup> Board meeting for the financial year ending 31 December 2020 (“**FY2020**”);
- (15) the announcement dated 17 February 2020 made by the Company in relation to the resolutions passed at the 1<sup>st</sup> Supervisory Committee meeting for FY2020;
- (16) the announcement dated 17 February 2020 made by the Company in relation to the repurchase and cancellation of some of the Restricted A-Shares granted under the Scheme;
- (17) the announcement dated 17 February 2020 made by the Company in respect of the notification to creditors of the Company in relation to the repurchase and cancellation of the Restricted A-Shares;
- (18) the announcement dated 6 July 2020 made by the Company in relation to the resolution passed at the 5<sup>th</sup> Board meeting for FY2020;
- (19) the announcement dated 6 July 2020 made by the Company in relation to the resolution passed at the 4<sup>th</sup> Supervisory Committee meeting for FY2020; and
- (20) the announcement dated 6 July 2020 made by the Company in relation to the grant of the Reserved Restricted A-Shares to the Participants under the Scheme.

Electronic copies of each of the aforementioned announcements and the Circular are available on the website of the Singapore Exchange Securities Trading Limited at <https://www.sgx.com/>.

*Unless otherwise defined, all capitalised terms used herein shall bear the same meanings ascribed to them in the Circular and the 2020 5<sup>th</sup> Board Meeting Announcement.*

**1. Allocation of the Reserved Restricted A-Shares to the Participants proposed to participate in the Grant of Reserved Restricted A-Shares**

<b>Personnel category</b>	<b>Number / designations</b>	<b>Number of Reserved Restricted A-Shares to be granted</b>	<b>Percentage of the total number of the Reserved Restricted A-Shares to be granted under the Scheme</b>	<b>Percentage of the total issued share capital of the Company as at date of the announcement of the Scheme</b>

Li Yan 李颜	Director and General Manager	70,000	1.44%	0.009%
Members of management team, leading-level scientific research experts, core personnel for scientific research and technology and members of core management team of subordinate enterprises of the Company (excluding the Company's associated companies)	25	870,000	17.86%	0.113%
Participants under the Initial Grant	115	3,930,000	80.70%	0.508%
<b>Total</b>	141	4,870,000	100%	0.63%

**2. List of the Participants who are members of the management team of the Company, leading-level scientific research experts, core personnel for scientific research and technology and members of core management team of subordinate enterprises of the Company**

S/No.	Name	Designation
1.	Xu Jia 徐佳	Member of middle-level management of the Company
2.	Zhang Rui 张睿	
3.	Gao Na 高娜	
4.	Wang Wei 王伟	

5.	Sui Rui 睢 锐	Core operation and management personnel of the Company's branches and subsidiaries
6.	Sun Lvheng 孙律衡	
7.	Liu Yilong 刘一龙	
8.	Rong Xin 荣 欣	
9.	Fu Lian 付 莲	
10.	Wang Cun 王 存	
11.	Hou Dongxu 侯东旭	
12.	Wu Yunjiao 吴芸蛟	
13.	Gao Mo 高 茉	
14.	Yan Chunjiang 闫春江	
15.	Han Liyun 韩立云	
16.	Li Hongming 李红明	
17.	Mei Zongyue 梅宗玥	
18.	Zhang Hui 张 辉	
19.	Xu Yan 徐 燕	
20.	Wang Wei 汪 伟	
21.	Zhang Hui 张 卉	
22.	Gao Jian 高 舰	
23.	Zhu Hongke 朱宏科	
24.	Hu Xiaoyuan 胡晓媛	
25.	Wang Qiang 王 强	

**By Order of the Board**

Jiao Yan  
Secretary to the Board  
6 July 2020